Cargando…
IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers
Head and neck squamous cell carcinoma (HNSCC) is an immunosuppressive malignancy characterized by tumor-driven immune-system abnormalities that contribute to disease progression. For patients with surgically resectable HNSCC, treatment is often curative surgery followed by irradiation or chemoradiat...
Autores principales: | Wolf, Gregory T, Moyer, Jeffrey S, Kaplan, Michael J, Newman, Jason G, Egan, James E, Berinstein, Neil L, Whiteside, Theresa L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029613/ https://www.ncbi.nlm.nih.gov/pubmed/29988729 http://dx.doi.org/10.2147/OTT.S165411 |
Ejemplares similares
-
Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen
por: Berinstein, Neil L., et al.
Publicado: (2018) -
Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells
por: Da Silva, Diane M., et al.
Publicado: (2016) -
IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells
por: Schilling, Bastian, et al.
Publicado: (2013) -
Peptide Based Vaccine Approaches for Cancer—A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen
por: Naylor, Paul H., et al.
Publicado: (2011) -
IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model
por: Schilling, Bastian, et al.
Publicado: (2011)